KOMATSU, Yasuhiro

English

Okayama University Scientific Achievement Repository

Supplementary Table 1 Patient information for 11 cases of colorectal cancer treated with the CAPOX-RT (capecitabine + oxaliplatin + radiotherapy) regimen Age (years) Sex Differentiation TNM Stage RAS/BRAF/MSI CEA (ng/mL) 53 M tub2 T2N0M0  2.6 60 M pap T3N0M0  16.18 63 M tub1 T3N0M0  16.73 88 F tub2 T2N0M0  4.11 61 M tub2 T2N1M0  4.13 75 F pap T3N0M0  4.94 44 F tub1 T3N1M0  1.28 69 M tub2 T3N0M0  1.73 81 F tub1 T3N1M0 KRAS G12C 6.4 45 F tub2 T2N2M0 NRAS G13R 3.17 83 M tub1 T3N3M0  3.89 MSI: microsatellite instability, CEA: Carcinoembryonic Antigen.  Supplementary Table 2: Primer sequences for PCR Primers for RNA editing site-specific quantitative PCR Gene Primer sequence Wild-type AZIN1 Forward: CATTCAGCTCAGGAAGAAGACATCT Reverse: AATACAAGGAAGATGAGCCTCTGTTTAC Edited AZIN1 Forward: ACTGAATGACATCATGTAATAAATGGCT Reverse: GAGCTTGATCAAATTGTGGCAG Wild-type GLI1 Forward: GGGGAGGACAGAACTTTGATCCTTACCT Reverse: CTGGCTCTTCCTGTAGCCCGCT Edited GLI1 Forward: ACTGAGAATGCTGCCATGGATGATG Reverse: AAGTCCATATAGGGGTTCAGACCACTGC Wild-type APOBEC3D Forward: GTCCAGGCTGGAATGCAATGTCA Reverse: GAGGCTGAAGCAGAAGAATCGCTTAAAC Edited APOBEC3D Forward: CTCTGGGATCTCTCTGCCTCCAAATATC Reverse: GAGGTTGCAGTGAGTCCAGATGGC Primers for RNA editing site-specific PCR using PrimeTime 5' Nuclease Assaya CCNI (human) Forward: CCAATTCAACCTTTACCCAGAA Reverse: TCAACAGTCTTGGCAGCTA Wild Probe: /5HEX/TTG+GA+T+A+G+GT+TT/3IABkFQ/ Edited Probe: /56-FAM/TGGA+T+G+GG+T+TT/3IABkFQ/ CCNI (mouse) Forward: CCAGTTCAACCTCTATCCAGAA Reverse: TCAACAGTCTTAGCAGCCA Wild Probe: /5HEX/TTG+GA+T+A+G+GT+TT/3IABkFQ/ Edited Probe: /56-FAM/TGGA+T+G+GG+T+TT/3IABkFQ/ Primers for qRT-PCR Gene Primer sequence ADAR1 (human) Forward: CCCTTCAGCCACATCCTTC Reverse: GCCATCTGCTTTGCCACTT IFNα (human) Forward: AATGACAGAATTCATGAAAGCGT Reverse: GGAGGTTGTCAGAGCAGA IFNβ (human) Forward: GCCATCAGTCACTTAAACAGC Reverse: GAAACTGAAGATCTCCTAGCCT ZBP1 (human) Forward: GCAAACTCCGAAGCCATCCAGA Reverse: CCAAGTTGAGGAATCACCTGGTG ADAR1 (mouse) Forward: GCCAAAGACAGTGGTCAACCAG Reverse: GAACAAGGATGTTGCTGAGGAGC GAPDH (mouse) Forward: CATCACTGCCACCCAGAAGACTG Reverse: ATGCCAGTGAGCTTCCCGTTCAG aObtained from IDT (Coralville, IA, USA).  Supplementary Figure 1                   A positive correlation was found between the expression level of ADAR1 in the nucleus and the surrounding lymphocyte population in chemoradiation therapy-treated colorectal cancers.    Supplementary Figure 2             ADAR1 expression in each cell line using realtime PCR. HT29 (ADAR1 high) and Caco2 (ADAR1 low) colorectal cancer cells were selected for cell line-based analyses.    Supplementary Figure 3                     ZBP1, RIP1, and RIP3 were upregulated in OX-RT treated CRC cells compared with the control. OX: Oxaliplatin; RT: Radiotherapy.   Supplementary Figure 4                   The level of ADAR1 staining was evaluated using intensity scores (1, very weak; 2, weak; 3, intermediate; 4, strong; and 5, very strong). IHC: Immunohistochemistry.   Supplementary Figure 5   The degree of RNA editing of CCNI was analyzed using a PrimeTime 5' Nuclease Assay (IDT, Coralville, IA, USA).    Supplementary Figure 6           Original image of Western Blotting in Figure 6C. OX: Oxaliplatin; RT: Radiotherapy. 

RNA編集は、結腸直腸癌においてオキサリプラチン・放射線療法同時投与中にネオアンチゲンの生成増強を促進する

https://ousar.lib.okayama-u.ac.jp/files/public/6/65343/20230607093553590061/K0006782_other_suppl.pdf

RNA編集は、結腸直腸癌においてオキサリプラチン・放射線療法同時投与中にネオアンチゲンの生成増強を促進する

Abstract

Similar works

Full text

Available Versions

Okayama University Scientific Achievement Repository